Initial chemosensitivity is known concerning SCLC but relapse is almost systematic, especially at a metastatic stage. Brain metastasis are identified around 40 to 50% during the evolution of the disease. Concerning the efficacy of epirubicin combined with paclitaxel from the second-line treatment, data is lacking more particularly about specific response on brain metastasis.

In this retrospective multicentric observational study in real life conditions, we try to evaluate systemic and specific cerebral efficacy and safety of a regimen combining epirubicin and paclitaxel in patients treated between 2010 and 2020 for a small cell lung carcinoma from the second-line treatment.

Inclusion Criteria:

• Adults (age ≥18 years)
• Histologically or cytologically SCLC diagnosis
• Treated with epirubicin-paclitaxel doublet between January 2010 and December 2020

Exclusion Criteria:

• Opposition to participate registered
• Patients under legal protection
• Patients afflicted by another subtype of lung carcinomas
• SCLC not treated with the epirubicin-paclitaxel doublet

Adults (age ≥18 years) with histologically or cytologically SCLC diagnosis was confirmed who received at least one cycle with a epirubicin-paclitaxel doublet treated between January 2010 and December 2020 in one of the three centers (Brest University Hospital Center, Quimper Hospital Center and Landerneau Hospital Center)

All collected data that underlie results in a publication

Data will be available beginning three month and ending five years following the publication

Data access requests will be reviewed by the internal committee of Brest UH. Requestors will be required to sign and complete a data access agreement.